This segment focuses on the research and development of small molecule medicines for brain conditions, particularly rare neurological disorders and epilepsies. Ovid Therapeutics employs a BoldMedicine® approach to develop treatments that transform the lives of patients. Key research areas include Angelman syndrome, Fragile X syndrome, cyclin-dependent kinase-like 5 deficiency disorder, and Dravet syndrome. The company is dedicated to improving the lives of people affected by these conditions through innovative drug discovery and clinical trials. This segment leverages strategic collaborations with academic institutions and other pharmaceutical companies to accelerate the development of new treatments and expand its product pipeline.

This segment is dedicated to the discovery and development of gene therapies for neurological disorders. Ovid Therapeutics is exploring OV882 as a short hairpin RNA gene therapy for the treatment of Angelman syndrome and OV815, a gene modulation therapy for the treatment of kinesin-family of proteins associated neurological disorder. The company collaborates with Columbia University Irving Medical Center to advance genetic research and accelerate the development of new treatments for rare neurological diseases. This segment focuses on cutting-edge technologies and methodologies to develop targeted therapies that address the underlying genetic causes of these disorders, with the goal of providing long-term benefits for patients.